The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK DIRECTOR DEALINGS SUMMARY: Braveheart Buys Stake In RMS From Brown

Wed, 01st Jul 2020 17:15

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Tuesday and Wednesday and not separately reported by Alliance News:

----------

Remote Monitored Systems PLC - London-based majority owner of GyroMetric Systems Ltd, which provides digital monitoring and safeguarding systems for rotating shafts on wind turbines - Braveheart Investment Group PLC buys 119.6 million shares from Executive Director Trevor Brown at 0.275 pence, worth GBP329,003, on Tuesday. Brown is chief executive officer of Braveheart, and payment for the RMS shares is in new Braveheart shares issued to Brown. Following the transaction, Braveheart owns 18.1% of RMS, and Brown has no interest. Brown now has a 24.8% stake in Braveheart. RMS owns 58% of GyroMetric and Braveheart owns 19.5%. Brown will remain on the RMS board to represent Braveheart.

----------

Savills PLC - London-based estate agent - James Sparrow, CEO of Savills UK & EMEA, sells 4,096 shares at GBP8.33, worth GBP34,100, on Friday last week. Still holds 58,475 shares.

----------

Babcock International Group PLC - London-based engineering services for defence - Chair Ruth Cairnie and associate buy 10,000 shares in total at GBP3.12 and GBP3.15, worth GBP31,333, on Wednesday.

----------

Qinetiq Group PLC - Farnborough, Hampshire-based security and defence contractor - Non-Executive Director Susan Searle buys 10,000 shares at GBP3.0244, worth GBP30,244, on Wednesday.

----------

Walker Greenbank PLC - Denham, Buckinghamshire-based interior furnishings - Non-Executive Director Christopher Rogers buys 52,500 shares at 37p, worth GBP19,425, on Tuesday. Now has 75,000 shares.

----------

Renew Holdings PLC - Leeds-based engineering services for infrastructure - Non-Executive Director Shatish Dasani and wife Dina buy 10,000 shares total at 444p, worth GBP44,400, on Tuesday. Dasani now interested in 15,000 shares.

----------

Staffline Group PLC - Nottingham-based recruitment and training firm - Three directors buy GBP70,857 in shares on Tuesday. Executive Chair Ian Lawson buys 131,577 shares at 39.00p, worth GBP51,315. Interim Chief Financial Officer Daniel Quint buys 25,320 shares at average 39.49p, worth GBP9,209. Non-Executive Director Richard Thomson buys 25,857 shares at average 39.96p, worth GBP10,333.

----------

Solid State PLC - Redditch, Worcestershire-based electronic components - Finance Director Peter James buys 2,520 shares at GBP5.95, worth GBP14,994. Now has 3,204 shares. Matthew Richards, managing director of subsidiary Steatite Ltd, buys 2,900 shares at GBP5.91, worth GBP17,126. Now has 10,375 shares. Both on Tuesday.

----------

ECSC Group PLC - Bradford-based cybersecurity firm - CEO Ian Mann buys 29,827 shares at average 67p, worth GBP19,984, on Wednesday. Now has 2.3 million shares, a 23% stake.

----------

Redx Pharma PLC - Macclesfield-based cancer and fibrosis drugs - Non-Executive Chair Iain Ross buys 215,870 shares at average 18.94p, worth GBP40,886, on Tuesday. Non-Executive Director Peter Presland buys 118,849 shares at 25p, worth GBP29,712, also on Tuesday. Both purchases are their only holdings.

----------

Trackwise Designs PLC - Tewkesbury, Gloucestershire-based printed circuit technology - Non-Executive Director Charles Cattaneo buys 10,000 shares at 86p, worth GBP8,600, on Tuesday. The shares are his only holding.

----------

UIL Ltd - closed-end Bermuda-incorporated investment company - Non-Executive Director Stuart Bridges buys 6,080 shares at 180p, worth GBP10,944, on Wednesday.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 May 2023 14:44

Redx Pharma half-year loss doubles amid costs of failed Jounce merger

(Alliance News) - Redx Pharma PLC on Wednesday said its half-year loss nearly doubled, due to lower revenue and higher expenses, but it noted progress in therapeutics trials and said it "retains the foundations for longer term success".

Read more
11 May 2023 18:17

IN BRIEF: Redx reports positive preclinical data for fibrosis drug

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company - Announces preclinical data for its lead fibrosis asset, RXC007, and the Discodin Domain Receptor 1/2 discovery programme, as presented yesterday at the Resistant Tumour Microenvironment, Keystone Symposia, in Vancouver. Notes the data presented were from preclinical models of pancreatic ductal adenocarcinoma and triple negative breast cancer in combination with chemotherapy and immunotherapy, as current standard of care. Says RXC007, in combination with gemcitabine/Abraxane in metastatic and high-extra cellular matrix patient-derived PDAC models, was shown to increase survival compared to single agent standard of care alone. The combination of RXC007 with standard of care provided a significant increase in median survival days from date of treatment in a dose dependent manner. These new data on RXC007 complement those also presented at the meeting by collaboration partner the Garvan Institute of Medical Research on REDX10616, a close analogue of RXC007. Taken together, these data provide a strong rationale for the potential of ROCK2 inhibition in combination with standard of care as a potential treatment for cancer-associated fibrosis. Redx plans to further investigate this treatment setting with the company's next-generation ROCK2 inhibitor, RXC007. Further, at the Keystone Symposia, data were also presented from Redx's DDR1/2 programme in combination with anti-PD-1 in TNBC models. Using a tool DDR1/2 inhibitor, in combination with anti-PD-1, in the TNBC E0771 model resulted in a statistically significant increase in survival when compared to the control group, an effect not observed with either single agent alone.

Read more
10 May 2023 15:45

UK earnings, trading statements calendar - next 7 days

Thursday 11 May 
3i Group PLCFull Year Results
Airtel Africa PLCFull Year Results
Eurocell PLCTrading Statement
Donegal Investment Group PLCHalf Year Results
Grainger PLCHalf Year Results
Hurricane Energy PLCFull Year Results
ICG Enterprise Trust PLCFull Year Results
IQE PLCFull Year Results
ITV PLCTrading Statement
John Wood Group PLCTrading Statement
Morgan Advanced Materials PLCTrading Statement
Rolls-Royce Holdings PLCTrading Statement
S4 Capital PLCQ1 Results
TBC Bank Group PLCQ1 Results
Friday 12 May 
Allianz Technology Trust PLCQ1 Results
Balfour Beatty PLCTrading Statement
Beazley PLCQ1 Results
CMO Group PLCFull Year Results
Monday 15 May 
CentralNic Group PLCFull Year Results
Cerillion PLCHalf Year Results
Currys PLCTrading Statement
Diploma PLCHalf Year Results
Equals Group PLCTrading Statement
Finsbury Growth & Income Trust PLCHalf Year Results
Instem PLCFull Year Results
JPMorgan Multi-Asset Growth & Income PLCFull Year Results
Westminster Group PLCFull Year Results
Tuesday 16 May 
Angling Direct PLCFull Year Results
boohoo Group PLCFull Year Results
Britvic PLCHalf Year Results
Burford Capital LtdFull Year Results
Cornerstone FS PLCFull Year Results
DCC PLCFull Year Results
Essentra PLCTrading Statement
Greggs PLCTrading Statement
Hyve Group PLCHalf Year Results
Imperial Brands PLCHalf Year Results
Land Securities Group PLCFull Year Results
Likewise Group PLCFull Year Results
Marston's PLCHalf Year Results
Renew Holdings PLCHalf Year Results
Smartspace Software PLCFull Year Results
Vodafone Group PLCFull Year Results
Zytronic PLCHalf Year Results
Wednesday 17 May 
Auction Technology Group PLCHalf Year Results
Bank of Georgia Group PLCQ1 Results
British Land Co PLCFull Year Results
Experian PLCFull Year Results
JD Sports Fashion PLCFull Year Results
Keller Group PLCTrading Statement
Ninety One PLC and LtdFull Year Results
Redx Pharma PLCHalf Year Results
Sage Group PLCHalf Year Results
Scottish Mortgage Investment Trust PLCFull Year Results
TP ICAP Group PLCQ1 Results
Watches of Switzerland Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2023 18:05

TRADING UPDATES: Redx confirms Jounce deal lapses, Tirupati seals deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
27 Mar 2023 14:34

Redx Pharma's bid to buy Jounce snubbed by Concentra's higher offer

(Alliance News) - Redx Pharma PLC on Monday noted that Jounce Therapeutics Inc, which it was close to buying, was bought by Concentra Biosciences LLC for a higher price.

Read more
27 Mar 2023 14:16

Jounce agrees Concentra Bioscences takeover, ditches Redx Pharma

(Sharecast News) - Jounce Therapeutics said on Monday that it was ditching a planned merger with AIM-listed Redx Pharma, opting instead to be bought by Concentra Bioscences.

Read more
8 Mar 2023 12:07

LONDON MARKET MIDDAY: Stocks down, pound below USD1.19 on US rate view

(Alliance News) - Stock prices in London were lower at midday on Wednesday, with investors still reeling from surprisingly hawkish comments by US Federal Reserve Chair Jerome Powell on Tuesday.

Read more
8 Mar 2023 11:52

Redx Pharma shares slide on RXC004 monotherapy blow

(Alliance News) - Redx Pharma PLC on Wednesday said first results of its phase 2 programme indicate were not sufficient enough to support the development of its RXC004 treatment as a monotherapy.

Read more
8 Mar 2023 10:42

AIM WINNERS & LOSERS: Redx drops on disappointing cancer drug results

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
7 Mar 2023 15:44

UK shareholder meetings calendar - next 7 days

Wednesday 8 March 
Amigo Holdings PLCGM re the company's capital position
boohoo Group PLCGM re adoption of the Growth Plan
Creo Medical Group PLCGM re open offer shares
Globalworth Real Estate Investments LtdEGM re grant options and script dividends
Henderson Opportunities Trust PLCAGM
Jersey Electricity PLCAGM
Thursday 9 March 
CT Capital & Income Investment Trust PLCAGM
Shoe Zone PLCAGM
WAG Payment Solutions PLCGM re proposed acquisition of Inelo
Friday 10 March 
Atrato Onsite Energy PLCAGM
Malin Corp PLCAGM
Mineral & Financial Investments LtdAGM
Monday 13 March 
BlackRock Energy & Resources Income Trust PLCAGM
Hercules Site Services PLCAGM
Hummingbird Resources PLCGM re strategic investment and placement
Ironveld PLCGM re second placing shares on AIM
Tuesday 14 March 
Georgia Capital PLCGM re company's transfer from Premium to Standard listing
MTI Wireless Edge LtdAGM
Redx Pharma PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
23 Feb 2023 10:24

Redx Pharma and Jounce Therapeutics agree transatlantic merger

(Alliance News) - Redx Pharma PLC and Jounce Therapeutics Inc on Thursday said they have agreed to an all-share merger that will create a USD425 million company focused on the treatment of cancer and fibrotic diseases.

Read more
23 Feb 2023 07:56

LONDON BRIEFING: WPP profit jumps in 2022; guides for further growth

(Alliance News) - Stocks in London were called to open slightly higher on Thursday, as investors were unfazed by a fairly uneventful set of policy meeting minutes from the US central bank.

Read more
9 Feb 2023 12:25

IN BRIEF: Redx Pharma makes progress on fibrosis candidate study

Redx Pharma PLC - Alderley Edge, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Updates on its lead fibrosis candidate, RXC007, which is currently being assessed in a phase 2a study. Says regulatory and ethics approvals for the 28-day and 12-week cohorts of the study have been received in five countries. Adds recruitment is progressing at a number of study sites, but says enrolment in the US 12-week cohort has not begun due to a partial US Food & Drug Adminstration hold, pending a data readout from an ongoing non-clinical programme. The requested data is expected later this year. US enrolment in the 28-day cohort is unaffected.

Read more
20 Dec 2022 14:29

EARNINGS SUMMARY: Goodwin achieves rise in interim profit and revenue

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
16 Dec 2022 21:22

TRADING UPDATES: Uniphar takeover fails; Pearson notes redemption end

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.